We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+26.41%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$939M
AUM Growth
-$111M
Cap. Flow
-$257M
Cap. Flow %
-27.36%
Top 10 Hldgs %
81.95%
Holding
25
New
3
Increased
2
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$70.7M
2
OBSV
ObsEva SA Ordinary Shares
OBSV
+$37.4M
3
DERM
Dermira, Inc.
DERM
+$17.2M
4
AKBA icon
Akebia Therapeutics
AKBA
+$12.4M
5
XLRN
Acceleron Pharma
XLRN
+$8.27M

Top Sells

Rank Stock Value
1
VTI icon
Vanguard Total Stock Market ETF
VTI
+$187M
2
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$115M
3
VGK icon
Vanguard FTSE Europe ETF
VGK
+$101M

Sector Composition

Rank Sector Weight
1 Healthcare 96.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INGN icon
1
Inogen
INGN
$169M
$275M 29.31%
3,549,320
– –
ANAB icon
2
AnaptysBio
ANAB
$1.64B
$84.2M 8.96%
+3,033,504
New +$70.7M
RETA
3
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$76.3M 8.12%
3,367,763
– –
IRTC icon
4
iRhythm Holdings
IRTC
$3.67B
$76.1M 8.11%
2,024,448
– –
CRVS icon
5
Corvus Pharmaceuticals
CRVS
$1.13B
$67M 7.13%
3,224,046
– –
RARX
6
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$43.3M 4.61%
2,031,562
– –
XLRN
7
DELISTED
Acceleron Pharma
XLRN
$41.1M 4.38%
1,553,937
+313,764
+25% +$8.27M
FLXN
8
DELISTED
Flexion Therapeutics, Inc.
FLXN
$37.6M 4.01%
1,397,718
– –
MRUS
9
DELISTED
Merus
MRUS
$34.4M 3.66%
1,410,417
– –
SPNC
10
DELISTED
Spectranetics Corp
SPNC
$34.3M 3.66%
1,179,122
– –
OBSV
11
DELISTED
ObsEva SA Ordinary Shares
OBSV
$31.7M 3.37%
+3,044,093
New +$37.4M
NBRV
12
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$27.9M 2.97%
9,306
– –
DERM
13
DELISTED
Dermira, Inc.
DERM
$25.5M 2.72%
748,240
+531,678
+246% +$17.2M
KALV
14
DELISTED
KalVista Pharmaceuticals
KALV
$22.7M 2.41%
2,901,927
– –
APEN
15
DELISTED
Apollo Endosurgery, Inc.
APEN
$18.2M 1.94%
1,456,972
– –
AKBA icon
16
Akebia Therapeutics
AKBA
$341M
$11.7M 1.25%
+1,272,247
New +$12.4M
IVTY
17
DELISTED
Invuity, Inc
IVTY
$10.5M 1.12%
1,318,448
– –
HTGM
18
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$8.86M 0.94%
7,112
– –
WMGIZ
19
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
– –
0
– –
CRSP icon
20
CRISPR Therapeutics
CRSP
$4.75B
$4.86M 0.52%
223,317
– –
XENE icon
21
Xenon Pharmaceuticals
XENE
$6.37B
$510K 0.05%
127,563
– –
OPK icon
22
Opko Health
OPK
$936M
$2K ﹤0.01%
259
– –
VGK icon
23
Vanguard FTSE Europe ETF
VGK
$30.2B
– –
-2,101,000
Closed -$101M
VTI icon
24
Vanguard Total Stock Market ETF
VTI
$660B
– –
-1,623,100
Closed -$187M
CLCD
25
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
– –
-3,156,563
Closed -$115M

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q1 2017 Portfolio in Review

As of Q1 2017, Novo Holdings A/S held 25 positions worth $939M, down 11% from $1.05B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Novo Holdings A/S withdrew a net $257M in Q1 2017, closing 3 positions. Its most notable exit was Vanguard Total Stock Market ETF, an estimated $187M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 71% a quarter earlier.

Against the trend, Novo Holdings A/S opened a new position in AnaptysBio worth $84.2M.

  • Novo Holdings A/S's largest Q1 2017 buy was AnaptysBio: 3,033,504 shares worth $84.2M.
  • Novo Holdings A/S added most to Dermira, Inc. in Q1 2017, an estimated $17.2M increase.
  • Novo Holdings A/S fully exited Vanguard Total Stock Market ETF in Q1 2017, selling an estimated $187M.
  • Novo Holdings A/S's ten largest holdings make up 82% of its $939M portfolio in Q1 2017.
  • Novo Holdings A/S opened 3 new positions and closed 3 in Q1 2017.
  • Novo Holdings A/S's portfolio value fell 11% quarter-over-quarter to $939M.

Based on Novo Holdings A/S's 13F filing for Q1 2017, filed 15 May 2017.